a Division of Nephrology , University Health Network and University of Toronto , Toronto , ON , Canada.
Expert Rev Mol Diagn. 2017 Oct;17(10):885-895. doi: 10.1080/14737159.2017.1358088. Epub 2017 Aug 13.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease that accounts for 5-10% of end-stage renal disease in developed countries. Mutations in PKD1 and PKD2 account for a majority of cases. Mutation screening of PKD1 is technically challenging largely due to the complexity resulting from duplication of its first 33 exons in six highly homologous pseudogenes (i.e. PKD1P1-P6). Protocol using locus-specific long-range and nested PCR has enabled comprehensive PKD1 mutation screening but is labor-intensive and costly. Here, the authors review how recent advances in Next Generation Sequencing are poised to transform and extend molecular diagnosis of ADPKD. Areas covered: Key original research articles and reviews of the topic published in English identified through PubMed from 1957-2017. Expert commentary: The authors review current and evolving approaches using targeted resequencing or whole genome sequencing for screening typical as well as challenging cases (e.g. cases with no detectable PKD1 and PKD2 mutations which may be due to somatic mosaicism or other cystic disease; and complex genetics such as bilineal disease).
常染色体显性多囊肾病(ADPKD)是最常见的遗传性肾脏疾病,占发达国家终末期肾病的 5-10%。PKD1 和 PKD2 的突变占大多数病例。由于其前 33 个外显子在六个高度同源的假基因(即 PKD1P1-P6)中重复,因此 PKD1 的突变筛查在技术上具有挑战性。使用基因座特异性长距离和嵌套 PCR 的方案已实现全面的 PKD1 突变筛查,但劳动强度大且成本高。在这里,作者回顾了下一代测序的最新进展如何改变和扩展 ADPKD 的分子诊断。涵盖领域:通过 PubMed 从 1957 年至 2017 年确定的有关该主题的关键原始研究文章和评论。专家评论:作者回顾了当前和正在发展的使用靶向重测序或全基因组测序的方法,用于筛查典型和具有挑战性的病例(例如,无法检测到 PKD1 和 PKD2 突变的病例,这些病例可能是由于体体细胞嵌合或其他囊性疾病引起的;以及复杂的遗传疾病,如双线性疾病)。